Ameridose LLC, sister company of the Massachusetts compounding pharmacy whose drugs have been implicated in a national fungal meningitis outbreak, has notified hundreds of workers that they are being laid off beginning Friday, as the company remains under a temporary closure order because of concerns about its sterility practices.
The layoff affects 650 workers at Westborough-based Ameridose, a major supplier of injectable drugs to hospitals nationwide, and 140 at its affiliated marketing company, Medical Sales Management of Framingham. Both companies share owners with New England Compounding Center, the Framingham company that produced steroid injections blamed for 424 cases of fungal meningitis and joint infections and 31 deaths.
“It was the company’s expectation that the suspension of operations would be temporary in nature and that we would be able to fully resume operations in a short time period,” reads a letter going out to workers from Ameridose’s director of human resources, Geri Weinstein.
“While we continue to expect to resume operations, we have now determined that because of the continued inspection by state and federal authorities, it may be necessary to resume operations at a reduced level,” the letter states.
About 200 of the layoffs are expected to be permanent because of the company’s loss of market share during its monthlong closure.
You have reached the limit of 5 free articles in a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than 25¢ a week